ISLCCC 2025
ISLCCC 2025 aims to feature emerging research results and insights from real world clinical experience to promote research collaborations and improve survivorship care throughout the world
Related Articles
Nurses Face Barriers When Discussing Sexuality as Part of Prostate Cancer Care – Oncology Nurse Advisor
Researchers identified barriers nurses encounter when discussing sexual health with patients with prostate cancer, according to an umbrella review
Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway
Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD,…
Amid a boom in organ donation, a heightened focus on cancer risk in transplant recipients
Click on the article title to read more.
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia
Key PointsPegC significantly decreased plasma glutamine and, in combination with Ven, disrupted messenger RNA translation.VenPegC induced complete remissio
Fakih Discusses Phase 2 Trial of Balstilimab Plus Botensilimab in MSS mCRC
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with…
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer…
Weiran Feng, Hanzhi Luo, Qing Chen join Fox Chase Cancer Center as assistant professors – The Cancer Letter
Weiran Feng, Hanzhi Luo and Qing Chen will join Fox Chase Cancer Center as assistant professors. To access this subscriber-only content please log in or…
Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer
Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.
Livestrong
What can we help you with today? Close search Livestrong Fertility If you’ve been diagnosed with cancer, we can help alleviate the burden of preserving…
Real-World Efficacy of Bispecific Antibodies for Patients With Relapsed or Refractory Large B-Cell Lymphomas
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes…
